Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMM0306 |
Synonyms | |
Therapy Description |
IMM0306 is a bispecific antibody-trap that targets both CD47 and CD20 expressed on B cells, potentially leading to inhibition of tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 545). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMM0306 | IMM-0306|IMM 0306 | CD20 Antibody 24 CD47 Antibody 31 | IMM0306 is a bispecific antibody-trap that targets both CD47 and CD20 expressed on B cells, potentially leading to inhibition of tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 545). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04746131 | Phase I | IMM0306 | Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) | Suspended | USA | 0 |